Market Outlook | FavStocks

EFI Reports Fourth Quarter and Full Year 2011 Results

26 January 2012 – 12:20 am PST

Comments Off

Q4′11 Revenue Increases 12% to a Record $163 Million Eighth Consecutive Quarter of Double-Digit Revenue Growth Q4′11 Non-GAAP EPS of $0.36, up 28% YoY FY’11 Revenue Increases 17% to $592 Million FY’11 Non-GAAP EPS of $1.12, up 90% YoY FOSTER CITY, Calif, Jan 24, 2012 (CRWENEWSWIRE) — Electronics For Imaging, Inc. (Nasdaq:EFII), a world [...]

(ELS, A, MHS, CRWE) Stock Report from PennyOmega.com

26 January 2012 – 12:20 am PST

Comments Off

Equity LifeStyle Properties, Inc. (NYSE:ELS) announced results for the three months and year ended December 31, 2011. For the three months ended December 31, 2011, Funds From Operations (”FFO”) were $43.5 million, or $0.96 per share on a fully-diluted basis, compared to $25.9 million, or $0.73 per share on a fully-diluted basis, for the same [...]

EUR/USD Down on Greek Discussion Stalemate

25 January 2012 – 12:25 am PST

Comments Off

EUR/USD was down today as talks about reducing Greek debt ended in a stalemate. Private creditors demand 4 percent interest rates, while Greece asked for less than 3 percent. The negative outcome of the discussion may result in a new wave of risk aversion on the Forex market. US data again was …

This Penny Stock Pump & Dump Has Lost $1.2 Billion But Is Up 450%+ In A Month

25 January 2012 – 12:24 am PST

Comments Off

This Penny Stock Pump & Dump Has Lost $1.2 Billion But Is Up 450%+ In A Month

UPDATE: Beautiful BVSN profits http://tim.ly/A0EIg9 and http://tim.ly/xAh3O1 and http://tim.ly/zykjBW from students who adapted & bought breakouts, but all of whom GREATLY underestimated this pump’s potential as did I. Please watch these brand new 7 free videos I just finished to …… .

(RDN, EFII, AAPL) PennyOmega.com Watch List for Wed Jan. 25, 2012

25 January 2012 – 12:24 am PST

Comments Off

AAPL, Apple Inc. ** AAPL reported financial results for its first quarter fiscal 2012, posting record quarterly revenue of $46.33 billion and record quarterly net profit of $13.06 billion, or $13.87 per diluted share. These results compare to revenue of $26.74 billion and net quarterly profit of $6 billion, or $6.43 per diluted share, in [...]

Polycom Reports Fourth Quarter and Fiscal Year 2011 Earnings

25 January 2012 – 12:24 am PST

Comments Off

PLEASANTON, CA — (CRWENEWSWIRE) 01/23/12 – Polycom, Inc. (NASDAQ:PLCM), the global leader in standards-based unified communications (UC), today reported its earnings for the fourth quarter and fiscal year ended December 31, 2011. Fourth quarter 2011 consolidated net revenues were a record $407 million, compared to $340 million for the fourth quarter of 2010. GAAP [...]

TearLab Osmolarity System CLIA Waiver Issued by FDA

25 January 2012 – 12:23 am PST

Comments Off

SAN DIEGO, Jan 24, 2012 (CRWENEWSWIRE) — TearLab Corporation (Nasdaq:TEAR) (TSX:TLB.TO) (”TearLab” or the “Company”) announced today that, after reviewing and accepting labeling submitted to it by the Company, the U.S. Food and Drug Administration (”FDA”) has now granted Waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 (”CLIA”) for the TearLab(R) [...]

(BLRX, TEAR, PLCM) PennyOmega.com Stocks In Action

25 January 2012 – 12:23 am PST

Comments Off

BLRX, BioLineRx Ltd. ** BLRX reported that it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. Hepatitis C infection is a blood borne infection of the liver caused by the Hepatitis C virus (HCV) [...]

BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C

25 January 2012 – 12:23 am PST

Comments Off

JERUSALEM — 01/24/2012 (CRWENEWSWIRE) — BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. BL-8020 has been developed for anti-viral therapy by Professor Philippe [...]

William Silhan Appointed as Military Products Sales Agent and Technical Consultant to AVEC Corporation

25 January 2012 – 12:22 am PST

Comments Off

DUBAI, United Arab Emirates, Jan. 24, 2012 (CRWENewswire) — AVEC Corporation (”AVEC”) (OTC Markets: AVEC.pk) announced today the appointment of William Silhan as Military Products Sales Agent and Technical Consultant. William F. (Billy) Silhan founded and was President of Pinpoint Systems International in 1990 after beginning his professional career at the Grumman Aerospace Corporation. To [...]